The company intends to use the funds to support submission of its NGS assay to the FDA, adoption of its testing by more health systems, and continued R&D.
The company now partners with 10 healthcare systems to provide free NGS testing to all advanced cancer patients and plans to present patient data this summer.
The company hopes to build enrollment of men with advanced prostate cancer within its larger Strata Trial — which provides free targeted sequencing and tracks its impact on clinical trial enrollment.
Strata will help Epizyme identify cancer patients for enrollment in a Phase II trial of its non-Hodgkins lymphoma drug tazemetostat.
Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.
The study will provide no-cost tumor sequencing and clinical trial matching to an estimated 100,000 patients with advanced cancers.
A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.
Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.
A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.
In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more